Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Taking The Higher Moral Ground, Medicines Australia Adopts Tougher Code Of Conduct

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Beginning January 2010, Medicines Australia member companies will need to adhere to a stricter Code of Conduct, which sets the ethical standard for marketing and promotion of prescription medicines in Australia

You may also be interested in...



Watchdog Tells Big Pharma In Australia To Disclose Sponsorship Payments By Early 2015

New rules on sponsorship payment disclosures to start by 2015; Medicines Australia members will begin to disclose aggregate data this year.

Pfizer Grilled By Australia’s TGA Over Payments To Pharmacists

Medicines Australia Calls For Level Playing Field For Ethical Conduct; Govt Not Likely To Intervene

PERTH, Australia - Following recent media reports of pharmaceutical outfits treating doctors to lavish outings, Medicines Australia is calling for a common standard of transparency and accountability for all companies operating in the therapeutics sector in Australia

Table

View full table

Related Content

Scrip
Tags:
Latest Headlines

Metsera Launches As New Obesity Contender Flush With $290m

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

See All
UsernamePublicRestriction

Register

SC070558

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By